Regeneron Pharmaceuticals, Inc.,, New York, United States
Disclosure information not submitted.
3C-06 - Mortality and hospitalization rates of adults with stable, chronic heart failure with reduced ejection fraction in the US, a claims analysis to inform clinical trial background rates
Monday, August 25, 20258:50 AM - 8:55 AM ET
6F-01 - One Disease, Three Definitions: Unpacking the Impact of Cohort Entry Date Choice on Type 2 Diabetes Identification Using Claims
Tuesday, August 26, 20251:30 PM - 1:45 PM ET
